Identification of the critical features of a small peptide inhibitor of JNK activity

被引:196
作者
Barr, RK
Kendrick, TS
Bogoyevitch, MA
机构
[1] Univ Western Australia, Cell Signaling Lab, Dept Biochem, Crawley, WA 6009, Australia
[2] Western Australian Inst Med Res, Perth, WA 6000, Australia
关键词
D O I
10.1074/jbc.M107565200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The c-Jun N-terminal kinases (JNKs) are a subfamily of the mitogen-activated protein kinases (NLAPKs). Although progress in evaluating the functions of other MAPKs has been facilitated by the characterization of specific inhibitors, no JNK-directed inhibitor is commercially available. We have identified a 21-amino acid peptide inhibitor of activated JNKs, based on amino acids 143-163 of the JNK-binding domain (JBD) of the JNK scaffolding protein, JNK-interacting protein-1 (JIP-1). This peptide, I-JIP (Inhibitor of JNK-based on JIP-1), inhibited JNK activity in vitro toward recombinant c-Jun, Elk, and ATF2 up to 90%. A truncated I-JIP (TI-JIP), the C-terminal 11 amino acids of I-JIP, directly interacted with recombinant JNKs but not its substrates as shown by surface plasmon resonance analysis. Scanning alanine replacement within truncated I-JIP identified 4 residues (Arg-156, Pro-157, Leu-160, or Leu-162) as independently critical for inhibition. JBD peptide sequences from JIP-2 and JIP-3 shared these critical residues and accordingly were effective JNK inhibitors. In contrast, peptides based on the JBDs of ATF2 and c-Jun inhibited JNK activity by <40%, which agreed with their lack of homology to the critical Arg-156 and Pro-157. These studies thus define a small peptide inhibitor sequence of JNKs based on the JIP proteins.
引用
收藏
页码:10987 / 10997
页数:11
相关论文
共 45 条
[1]   Regulation of JNK signaling by GSTp [J].
Adler, V ;
Yin, ZM ;
Fuchs, SY ;
Benezra, M ;
Rosario, L ;
Tew, KD ;
Pincus, MR ;
Sardana, M ;
Henderson, CJ ;
Wolf, CR ;
Davis, RJ ;
Ronai, Z .
EMBO JOURNAL, 1999, 18 (05) :1321-1334
[2]   PD-098059 IS A SPECIFIC INHIBITOR OF THE ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE KINASE IN-VITRO AND IN-VIVO [J].
ALESSI, DR ;
CUENDA, A ;
COHEN, P ;
DUDLEY, DT ;
SALTIEL, AR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (46) :27489-27494
[3]   A conserved docking site in MEKs mediates high-affinity binding to MAP kinases and cooperates with a scaffold protein to enhance signal transmission [J].
Bardwell, AJ ;
Flatauer, LJ ;
Matsukuma, K ;
Thorner, J ;
Bardwell, L .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (13) :10374-10386
[4]   SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase [J].
Bennett, BL ;
Sasaki, DT ;
Murray, BW ;
O'Leary, EC ;
Sakata, ST ;
Xu, WM ;
Leisten, JC ;
Motiwala, A ;
Pierce, S ;
Satoh, Y ;
Bhagwat, SS ;
Manning, AM ;
Anderson, DW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (24) :13681-13686
[5]   IB1 reduces cytokine-induced apoptosis of insulin-secreting cells [J].
Bonny, C ;
Oberson, A ;
Steinmann, M ;
Schorderet, DF ;
Nicod, P ;
Waeber, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (22) :16466-16472
[6]   Cell-permeable peptide inhibitors of JNK novel blockers of β-cell death [J].
Bonny, C ;
Oberson, A ;
Negri, S ;
Sauser, C ;
Schorderet, DF .
DIABETES, 2001, 50 (01) :77-82
[7]   CEP-1347/KT7515, a JNK pathway inhibitor, supports the in vitro survival of chick embryonic neurons [J].
Borasio, GD ;
Horstmann, S ;
Anneser, JMH ;
Neff, NT ;
Glicksman, MA .
NEUROREPORT, 1998, 9 (07) :1435-1439
[8]   Transactivation of naturally occurring HIV-1 long terminal repeats by the JNK signaling pathway - The most frequent naturally occurring length polymorphism sequence introduces a novel binding site for AP-1 factors [J].
Chen, PF ;
Flory, E ;
Avots, A ;
Jordan, BWM ;
Kirchhoff, F ;
Ludwig, S ;
Rapp, UR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (27) :20382-20390
[10]   Signal transduction by the JNK group of MAP kinases [J].
Davis, RJ .
CELL, 2000, 103 (02) :239-252